Relevant bibliographies by topics / Antidepressant medications

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Antidepressant medications'

Author: Grafiati
Published: 4 June 2021
Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antidepressant medications.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antidepressant medications"

1

Adams, Nicholas Norman. "Do Newer Antidepressant Drugs Really Have Reduced Side Effects? Examining a Random “Real World” Sample of 300+ Receivers of Medications." IAFOR Journal of Psychology & the Behavioral Sciences 6, no. 1 (December 12, 2020): 75–100. http://dx.doi.org/10.22492/ijpbs.6.1.05.

Full text
Abstract:
Newer antidepressant drugs are frequently cited as having reduced side effect profiles to that of their older counterparts. However, recent studies have begun to dispute this claim, citing selective sampling, short clinical trials, and clinical trial environments as influencing reported outcomes. At present, little research on antidepressant side effects draws on RWD (Real-World Data). Despite this, interest in examining RWD samples for antidepressant drug side effects is increasing as of 2020. The reported study asked a random sample of 300+ individuals taking a variety of different antidepressant medications to complete online drug side effect self-report scales with previously high validity. Newer antidepressants belonging to the atypical antidepressant drug class were reported as having only slightly reduced side effects of weight gain compared with older SSRI-class medications. No reduced side effects of increased depression, anxiety, sexual dysfunction (SD), sleepiness, or suicidal ideation (SI) were found for the newer atypical-class medications vs older SSRI-class agents. Medication adherence did not differ significantly between SSRI and atypical classes. No evidence for reduced side effects was found for newer SSRI and atypical antidepressants vs older same-class drugs when comparing six new and old medications drawn from atypical and SSRI classes. However, atypical antidepressants were associated with increased use of adjunct medications to bolster primary treatment.
APA, Harvard, Vancouver, ISO, and other styles
2

Webb, Lauren M., Kathryn E. Phillips, Man Choi Ho, Marin Veldic, and Caren J. Blacker. "The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review." International Journal of Molecular Sciences 21, no. 3 (January 28, 2020): 826. http://dx.doi.org/10.3390/ijms21030826.

Full text
Abstract:
Major depressive disorder (MDD) is the leading cause of disability worldwide and is associated with high rates of suicide and medical comorbidities. Current antidepressant medications are suboptimal, as most MDD patients fail to achieve complete remission from symptoms. At present, clinicians are unable to predict which antidepressant is most effective for a particular patient, exposing patients to multiple medication trials and side effects. Since MDD’s etiology includes interactions between genes and environment, the epigenome is of interest for predictive utility and treatment monitoring. Epigenetic mechanisms of antidepressant medications are incompletely understood. Differences in epigenetic profiles may impact treatment response. A systematic literature search yielded 24 studies reporting the interaction between antidepressants and eight genes (BDNF, MAOA, SLC6A2, SLC6A4, HTR1A, HTR1B, IL6, IL11) and whole genome methylation. Methylation of certain sites within BDNF, SLC6A4, HTR1A, HTR1B, IL11, and the whole genome was predictive of antidepressant response. Comparing DNA methylation in patients during depressive episodes, during treatment, in remission, and after antidepressant cessation would help clarify the influence of antidepressant medications on DNA methylation. Individuals’ unique methylation profiles may be used clinically for personalization of antidepressant choice in the future.
APA, Harvard, Vancouver, ISO, and other styles
3

Antonuccio, David, and David Healy. "Relabeling the Medications We Call Antidepressants." Scientifica 2012 (2012): 1–6. http://dx.doi.org/10.6064/2012/965908.

Full text
Abstract:
This paper raises the question about whether the data on the medications we call antidepressants justify the label of antidepressant. The authors argue that a true antidepressant should be clearly superior to placebo, should offer a risk/benefit balance that exceeds that of alternative treatments, should not increase suicidality, should not increase anxiety and agitation, should not interfere with sexual functioning, and should not increase depression chronicity. Unfortunately, these medications appear to fall short on all of these dimensions. Many of the “side effects” of these medications have larger effect sizes than the antidepressant effect size. To call these medications antidepressants may make sense from a marketing standpoint but may be misleading from a scientific perspective. Consumers deserve a label that more accurately reflects the data on the largest effects and helps them understand the range of effects from these medications. In other words, it may make just as much sense to call these medications antiaphrodisiacs as antidepressants because the negative effects on libido and sexual functioning are so common. It can be argued that a misleading label may interfere with our commitment to informed consent. Therefore, it may be time to stop calling these medications antidepressants.
APA, Harvard, Vancouver, ISO, and other styles
4

Istilli, Plínio Tadeu, Adriana Inocenti Miasso, Cláudia Maria Padovan, José Alexandre Crippa, and Carlos Renato Tirapelli. "Antidepressants: knowledge and use among nursing students." Revista Latino-Americana de Enfermagem 18, no. 3 (June 2010): 421–28. http://dx.doi.org/10.1590/s0104-11692010000300018.

Full text
Abstract:
This study examined the knowledge of nursing students in regard to using antidepressant medication and proposes actions such that nurses contribute to a safe and effective antidepressant therapy. This cross-sectional and descriptive study was conducted in a public nursing school in the state of São Paulo, Brazil, between March and November 2008. Fifty-two (19%) out of the 273 participants were using or had used antidepressants. Instruction concerning the use of antidepressants was provided by physicians. Even after receiving instruction concerning the antidepressant treatment before its administration, the majority of users (cII1=0.07, p> 0.05) still had doubts about its use. Fluoxetine was the most prevalent antidepressant. Actions to improve knowledge concerning the use of antidepressant medications, their side and therapeutic effects, seem to be necessary and relevant.
APA, Harvard, Vancouver, ISO, and other styles
5

Sabella, Donna. "Antidepressant Medications." AJN, American Journal of Nursing 118, no. 9 (September 2018): 52–59. http://dx.doi.org/10.1097/01.naj.0000544978.56301.f6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Palus, Timefey. "Antidepressant Medications: Placebo Effects of Various Drugs." Neuroscience and Neurological Surgery 3, no. 1 (November 2, 2018): 01–02. http://dx.doi.org/10.31579/2578-8868/045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Antimisiaris, Demetra, Brittany McHolan, Daniela Moga, and Cortney Mospan. "Medication Related Problems." Senior Care Pharmacist 36, no. 2 (February 1, 2021): 68–82. http://dx.doi.org/10.4140/tcp.n.2021.68.

Full text
Abstract:
When selecting and managing psychoactive medications in older people, it is equally important to focus on avoidance of toxicity as it is to focus on efficacy. Higher psychoactive medication load is associated with increased rate and risk of all cause hospitalization. The medication classes used to treat depression and related comorbidities include antidepressants, antipsychotics, stimulants, mood stabilizers, lithium, anxiolytics and sedative hypnotics. This discussion will examine considerations to help avoid medication related problems relevant to medications used to treat depression in the antidepressant pharmacological class.
APA, Harvard, Vancouver, ISO, and other styles
8

Antimisiaris, Demetra, Brittany McHolan, Daniela Moga, and Cortney Mospan. "Medication Related Problems." Senior Care Pharmacist 36, no. 2 (February 1, 2021): 68–82. http://dx.doi.org/10.4140/tcp.n.2021.68.

Full text
Abstract:
When selecting and managing psychoactive medications in older people, it is equally important to focus on avoidance of toxicity as it is to focus on efficacy. Higher psychoactive medication load is associated with increased rate and risk of all cause hospitalization. The medication classes used to treat depression and related comorbidities include antidepressants, antipsychotics, stimulants, mood stabilizers, lithium, anxiolytics and sedative hypnotics. This discussion will examine considerations to help avoid medication related problems relevant to medications used to treat depression in the antidepressant pharmacological class.
APA, Harvard, Vancouver, ISO, and other styles
9

Thommasen, Harvey V., Earle Baggaley, Carol Thommasen, and William Zhang. "Prevalence of Depression and Prescriptions for Antidepressants, Bella Coola Valley, 2001." Canadian Journal of Psychiatry 50, no. 6 (May 2005): 346–52. http://dx.doi.org/10.1177/070674370505000610.

Full text
Abstract:
Objective: To determine the prevalence of depression–anxiety disorders and the degree to which physicians prescribed antidepressants for Aboriginal and non-Aboriginal populations living in a remote rural community in British Columbia in 2001. Methods: To obtain data for our main outcome measures, we retrospectively reviewed the charts of 2375 patients living in the Bella Coola Valley as of September 2001 and attending the Bella Coola Medical Clinic. Results: The 2001 prevalence rate of depression–anxiety disorders in the Bella Coola Valley was 7.5% (177/2375). Depression was the most common problem (86%) in these patients. Women had a higher rate of depression–anxiety disorders (10.3%) than did men (4.7%) ( P < 0.001). Non-Aboriginal people had a slightly higher rate (8.5%) than did Aboriginal people (6.3%); however, the difference was not statistically significant. Antidepressant medications were commonly prescribed for chronic pain and insomnia. The general pattern of antidepressant medication use in 2001 among both Aboriginal and non-Aboriginal people living in the Bella Coola Valley was as follows: peak use of antidepressants was in the middle to late years; the rate for women was roughly double the rate for men; and proportionately more Aboriginal people, especially the women, were taking antidepressants. Conclusions: Depression–anxiety disorder prevalence rates for Aboriginal and non-Aboriginal populations are similar. When using antidepressant medication prescriptions as a community health indicator, health care administrators should be aware that antidepressant medications are commonly prescribed for conditions other than depression–anxiety disorder.
APA, Harvard, Vancouver, ISO, and other styles
10

Saraghi, Mana, Leonard Golden, and Elliot V. Hersh. "Anesthetic Considerations for Patients on Antidepressant Therapy – Part II." Anesthesia Progress 65, no. 1 (March 1, 2018): 60–65. http://dx.doi.org/10.2344/anpr-65-01-10.

Full text
Abstract:
Millions of patients take antidepressant medications in the United States for the treatment of depression or anxiety disorders. Some antidepressants are prescribed off-label to treat problems such as chronic pain, low energy, and menstrual symptoms. Antidepressants are a broad and expansive group of medications, but the more common drug classes include tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and monoamine oxidase inhibitors. A miscellaneous or “atypical” category covers other agents. Some herbal supplements that claim to have antidepressant activity will also be discussed. Part I of this series reviewed antidepressant pharmacology, adverse effects, and drug interactions with adrenergic agonists. In part II, drug–drug interactions with sedation and general anesthetics, bleeding effects, and serotonin syndrome will be discussed.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antidepressant medications"

1

Fulton-Kehoe, Deborah. "Use of antidepressant medications in relation to the incidence of breast cancer /." Thesis, Connect to this title online; UW restricted, 2005. http://hdl.handle.net/1773/10941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ashbury, Janet E. "Selective serotonin reuptake inhibitors (SSRIs) and breast cancer : a record linkage study." Thesis, Kingston, Ont. : [s.n.], 2008. http://hdl.handle.net/1974/971.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sekar, Sakthivel. "Investigation of Neuronal Effects of Anxiogenic and Antidepressant Medications using Pharmacological Magnetic Resonance Imaging." Thesis, University of Newcastle Upon Tyne, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.519474.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gribbin, Jonathan. "Falls in older people and the role of commonly prescribed antidepressant and antihypertensive medications." Thesis, University of Nottingham, 2013. http://eprints.nottingham.ac.uk/28451/.

Full text
Abstract:
Background Falls in older people result in harm for individuals and are a major public health problem, but there is little published data on the recording and incidence of falls seen in primary care, with which to consider the implications of recent policy initiatives. A range of factors contribute to falls risk. Amongst these, the role of some medications is well established, but the evidence base regarding the effects of some of the most commonly prescribed medications remains meagre and inconsistent. Aims The project aims to quantify the overall incidence and distribution of recorded falls among older people in primary care in the UK, and the associated risk of death. The falls risk profile of more recently introduced serotonin noradrenalin reuptake inhibitors (SNRls) is explored to assess whether it is more favourable than that of selective serotonin reuptake inhibitors (SSRls). Similarly, prescribing of subclasses of antihypertensive medication is explored to establish whether any of them modify risk of falling. Finally, other classes or sub-classes of medication prescribed in primary care are identified whose apparent falls risk warrants further investigation. Methods Analysis of falls and prescribing history in the electronic records of patients aged 60 years and over from The Health Improvement Network (THIN) using cohort, survival, case-control and case series study designs. Results Amongst people aged >60 years the overall crude incidence rate of recorded falls was 3.58/100 person-years (3.56-3.61), higher in older age groups, in women and least advantaged social groups, and was constant in the period 2003-2006. Fallers experienced a substantial increase in mortality (two-fold increase for recurrent fallers, and more than five-fold for those aged 60-74 years). This increase is independent of fractures recorded at the time of the fall or subsequently. People who fall have an increased rate of subsequent fracture (approximately three-fold and, for recurrent fallers aged 60-74 years more than eight-fold). There was an increased risk of current prescribing of SNRls (adjusted OR 1.79, 1.42 - 2.25) in first fall cases compared with controls. This was similar in magnitude to that seen with tricyclic antidepressants and SSRls. The increase in risk was apparent within the first 28 days after first prescription. The effects were also apparent in the self-controlled case series analysis: the incidence risk ratio for the period 1-28 days after initiation of treatment compared with unexposed periods was 1.49 (1.15 - 1.93). There was an increased risk of current prescribing of thiazides (adjusted OR 1.28, 1.16-1.42). At 3 weeks after first prescribing the adjusted risk remained 4.28 (1.19-15.42). In the case series analysis the incidence risk ratio for the period 21 days after first prescription was 2.80 (1.7 - 4.57). We found a reduced risk for current prescribing of beta blockers (adjusted OR 0.90; 0.85- 0.96), but a weakly positive effect in the case series analysis for the corresponding period IRR 1.23 (1.02-1.48). Taken together, the case-control and case series analyses of other subclasses of antihypertensives provided weak or no evidence for an effect on falls. In the hypothesis generating case-control analysis of other medication classes, unadjusted odds ratios of greater than 1.7 were found in a number of classes of medication including: laxatives, antifungals, corticosteroids, insulin, antibiotics for mild to moderate acne, and vaccines for influenza and other infections. Conclusions Older people with a recorded fall represent a group who are at increased risk of death, irrespective of whether they have a subsequent fracture. Nevertheless the incidence of falls recorded in primary care suggests that guidance about asking patients if they have fallen in the last year appears not to have been followed during the study period. The fact that the incidence rate of falls is strongly associated with social disadvantage suggests the need to target the design and delivery of interventions accordingly. The falls risk profile of SNRls, which is similar to that of SSRls and TCAs, suggests that clinicians initiating prescribing of SNRls should be alert to the increased risk of falls. Similarly, clinicians initiating prescribing of thiazides in older people, which has generally been considered a 'safe' option for older patients, should be alert to the possibility of an increased risk of falls in the first three weeks of prescribing. Case series analysis of recurrent periodic exposures can elucidate bias in classis case-control analysis of the same data, and will be useful in assessing the falls risk profile of other medications such as insulin. Given the small size of sources of detailed data about older people who fall and the imprecision in their measurement of exposure to medications and potential confounders, case-control and case series analysis of first falls in THIN represents a valuable source of new evidence about medication risk factors.
APA, Harvard, Vancouver, ISO, and other styles
5

Cui, Ling 1978. "A comparative study of the diffusion of antihypertensive and antidepressant medications in Germany in Japan." Thesis, Massachusetts Institute of Technology, 2005. http://hdl.handle.net/1721.1/32283.

Full text
Abstract:
Thesis (S.M.)--Massachusetts Institute of Technology, Engineering Systems Division, Technology and Policy Program, 2005.
Includes bibliographical references (p. 137-141).
This thesis analyzes and compares the diffusion of antihypertensive and antidepressant medications in Germany and Japan during the time period of 1992 and 2003. The antihypertensive medications are classified as new, middle and old generations and the antidepressants are classified as new and old generations in this study. The demographic, economic, price, promotional, regulatory, and cultural factors that contributed to the sales level, number of compounds available in the market, and launch time of these medications are also examined using quantitative and qualitative methods at therapeutic class, generation, as well as product levels. The qualitative analysis includes discussions on the general health care systems, health care polices, and country-specific hypertension- and depression-related cultural backgrounds. Econometric tools (descriptive statistics and linear regression models) are used as means of quantitative analysis. The diffusion of different generations of medications is examined. The degree of the use of branded vs. generic medications are also compared. Finally, Chow-tests are conducted for cross-country and cross- therapeutic-class comparisons. This study finds that there are significant branded-v-generic, cross-generation, cross- class, cross-country differences in the diffusion of the selected therapeutic classes in the two countries. The factors examined contributed to the diffusion to various extents. Among which, the cultural factor played an important role in the adoption and sales of new medications of both therapeutic classes in both countries, especially the antidepressants in Japan. The promotional factors appear not to be very significant in the sales volumes, partially due to the regulatory settings of the two national-based health care systems.
y Ling Cui.
S.M.
APA, Harvard, Vancouver, ISO, and other styles
6

Ghanem, Simon. "Inflammation in young Swedish men and risk of adult-onset depression defined by prescription of antidepressant medications." Thesis, Örebro universitet, Institutionen för medicinska vetenskaper, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-86370.

Full text
Abstract:
Background: Depression is a major disability that has been studied extensively in regard to systemic inflammation. Cross-sectional studies have shown that systemic inflammatory parameters are raised in individuals with depression, but few studies have explored the longitudinal direction of associations. The aim of this study is to investigate whether heightened ESR-levels during adolescence increases the risk of subsequent depression during adulthood measured by antidepressant medication. Methods: This register-based cohort study included 196,667 Swedish men who were born in 1952 to 1956, attended mandatory military conscription assessments in late adolescence, and were followed up to 2009 through linkages of various national registers. The association between erythrocyte sedimentation rate, measured at conscription examination, and antidepressant treatment in middle age was examined using logistic regression with adjustment for confounding by BMI, stress resilience, socioeconomic index and household crowding. Results: Erythrocyte sedimentation rate was not positively associated with an increased subsequent risk of antidepressant treatment. The characteristics of >18,5 BMI, low stress resilience, lower household crowding and the socioeconomic index belonging to ‘office worker’, were of higher risk for antidepressant treatment. Conclusion: This study shows that the systemic inflammatory marker erythrocyte sedimentation rate is not positively associated with subsequent development of depression defined by antidepressant treatment.
APA, Harvard, Vancouver, ISO, and other styles
7

Åkerblad, Ann-Charlotte. "Adherence to Antidepressant Medication." Doctoral thesis, Uppsala University, Department of Neuroscience, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7769.

Full text
Abstract:

Non-adherence to medication is a major obstacle in the treatment of depression. The objectives of the present study were to explore the effect of two interventions aiming to increase antidepressant treatment adherence, and to examine long-term consequences and costs of depression in adherent and non-adherent primary care patients.

A randomised controlled design was used to assess the respective effects of a written educational adherence enhancing programme and therapeutic drug monitoring in patients with major depression treated with sertraline for 24 weeks. All patients were prospectively followed during two years.

Treatment adherence was found in 41% of the 1031 included patients. None of the interventions resulted in a significant increase in adherence rate. However, significantly more patients in the group receiving the written educational material had responded at week 24 as compared to patients in the control group.

The overall remission rate after two years was 68%. In total, 34% of the responders experienced at least one relapse. Response and remission rates at week 24, year 1 and year 2 were significantly higher in adherent as compared to non-adherent patients. No relationship between adherence and relapse rate was seen.

The mean total cost per patient during two years was KSEK 363 whereof indirect costs represented 87%. No significant differences in costs between intervention groups or between adherent and non-adherent patients could be demonstrated. However, the mean cost per patient was 39% lower for treatment responders as compared to non-responders.

Non-adherence was predicted by age below 35 or above 64 years, no concomitant medications, personality disorder, sensation seeking personality traits and substance abuse.

The results indicate a strong positive relationship between treatment adherence and clinical outcome. In addition, the study shows that depression is a costly disease and that certain patient characteristics predict non-adherence.

APA, Harvard, Vancouver, ISO, and other styles
8

Åkerblad, Ann-Charlotte. "Adherence to antidepressant medication /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7769.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cotterchio, Michelle. "Antidepressant medication use and breast cancer risk." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape9/PQDD_0007/NQ41131.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gallagher, Shawn Patrick, and Shawn Patrick Gallagher. "Antidepressant Medication Adherence in Active Duty Army Soldiers." Diss., The University of Arizona, 2017. http://hdl.handle.net/10150/626157.

Full text
Abstract:
Depression can be painful, disabling, and result in fatal consequences. The most common treatment, antidepressant medication, can effectively treat depressive symptoms. Though, adhering to antidepressant medication treatment is a complex phenomenon that can elude even the most informed who suffers from depression. While much is known about antidepressant medication adherence in the general population, there is a dearth of knowledge about it in active duty United States Army soldiers with depression. The purpose of this research was to explore antidepressant adherence among United States Army soldiers with depression in relation to the potential correlates of illness perceptions, beliefs about medication, social support, and selected demographic variables. This descriptive study analyzed findings to determine significant correlations or predictors of antidepressant adherence in soldiers with depression. Fifty-one participants, ranging from 24 to 36 years of age (M= 29 years of age) were recruited through Facebook™ (i.e., social media). After answering basic demographic and ‘insider’ knowledge, screening questions participants completed measures of medication adherence, illness perceptions, social support, depression, anxiety, post-traumatic stress, and alcohol use. Age and gender were the only variables significantly associated with medication adherence (r= -0.317, p= 0.024 and r= -0.331, p= 0.018) respectively and the only predictors of antidepressant medication adherence (R2= 0.206, Adjusted R2: 0.173, F: 6.234, p= 0.004). Antidepressant adherence scores indicated low levels of adherence. The findings of this study suggest those who are younger and are female United States Army soldiers may be more likely to report higher levels of antidepressant adherence.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Antidepressant medications"

1

Tranquillizers and antidepressants: When to take them, how to stop. London: Sheldon, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Painkillers and tranquilisers. Oxford: Heinemann Library, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Badger, Frances. Medication management for people with depression in primary care. [Birmingham]: University of Birmingham, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Deborah, Kotz, ed. The antidepressant survival program: How to beat the side effects and enhance the benefits of your medication. New York: Crown Publishers, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hedaya, Robert J. The antidepressant survival guide: The clinically proven program to enhance the benefits and beat the side effects of your medication. New York: Three Rivers Press, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

United States. Congress. House. Committee on Veterans' Affairs. Exploring the relationship between medication and veteran suicide: Hearing before the Committee on Veterans' Affairs, U.S. House of Representatives, One Hundred Eleventh Congress, second session, February 24, 2010. Washington: U.S. G.P.O., 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

The Evidencebased Guide To Antidepressant Medications. American Psychiatric Publishing, Inc., 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lam, Raymond W. Pharmacotherapy. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199692736.003.0007.

Full text
Abstract:
• The newer antidepressants (SSRIs, SNRIs, other receptor agents) are first-line medications due to improved safety and tolerability over first-generation medications (TCAs, MAOIs).• Selection of an antidepressant must take into account efficacy, depression subtype, safety, side effect profile, simplicity of use, comorbid conditions, concurrent medications, and cost....
APA, Harvard, Vancouver, ISO, and other styles
9

Tolin, David F., and Blaise L. Worden. Combining Pharmacotherapy and Psychological Treatments for OCD. Edited by Gail Steketee. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195376210.013.0081.

Full text
Abstract:
This chapter reviews the outcome literature on the efficacy of combined pharmacotherapy and cognitive-behavioral therapy (CBT) for obsessive compulsive disorder (OCD). By far, most research on combinations of CBT and pharmacotherapy for OCD has examined antidepressant medications, particularly those in the serotonin reuptake inhibitor (SRI) class. Quantitative review of randomized studies in which treatments were combined simultaneously indicated that combined therapy shows a small but significant advantage over exposure and response prevention (ERP) monotherapy, and a moderate advantage over pharmacologic (antidepressant) monotherapy. Studies of sequential treatment combination, in which CBT was added after a trial of antidepressant medication, suggest a significant incremental benefit of CBT, including for patients who show minimal response to antidepressant medication alone. The chapter concludes by discussing new pharmacologic possibilities for combined therapy, such as the use of D-cycloserine (DCS).
APA, Harvard, Vancouver, ISO, and other styles
10

Tolin, David F., and Blaise L. Worden. Combining Pharmacotherapy and Psychological Treatments for OCD. Edited by Gail Steketee. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195376210.013.019_update_001.

Full text
Abstract:
This chapter reviews the outcome literature on the efficacy of combined pharmacotherapy and cognitive-behavioral therapy (CBT) for obsessive compulsive disorder (OCD). By far, most research on combinations of CBT and pharmacotherapy for OCD has examined antidepressant medications, particularly those in the serotonin reuptake inhibitor (SRI) class. Quantitative review of randomized studies in which treatments were combined simultaneously indicated that combined therapy shows a small but significant advantage over exposure and response prevention (ERP) monotherapy, and a moderate advantage over pharmacologic (antidepressant) monotherapy. Studies of sequential treatment combination, in which CBT was added after a trial of antidepressant medication, suggest a significant incremental benefit of CBT, including for patients who show minimal response to antidepressant medication alone. The chapter concludes by discussing new pharmacologic possibilities for combined therapy, such as the use of D-cycloserine (DCS).
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Antidepressant medications"

1

Early, Maureen, Logan Wink, Craig Erickson, and Christopher J. McDougle. "Antidepressant Medications." In Encyclopedia of Autism Spectrum Disorders, 187–91. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1698-3_815.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Abrams, David B., J. Rick Turner, Linda C. Baumann, Alyssa Karel, Susan E. Collins, Katie Witkiewitz, Terry Fulmer, et al. "Antidepressant Medications." In Encyclopedia of Behavioral Medicine, 101–3. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_1231.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Akechi, Tatsuo. "Antidepressant Medications." In Encyclopedia of Behavioral Medicine, 120–21. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_1231.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Early, Maureen, Logan Wink, Craig A. Erickson, and Christopher J. McDougle. "Antidepressant Medications." In Encyclopedia of Autism Spectrum Disorders, 239–43. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-319-91280-6_815.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Desai, Jignyasa. "Neuropathic Antidepressant Medications." In Pain Management and Palliative Care, 75–83. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2462-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Carboni, Lucia, Chiara Piubelli, and Enrico Domenici. "Proteome Effects of Antidepressant Medications." In Genomics, Proteomics, and the Nervous System, 399–441. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-7197-5_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lam, Siu Ping, Jihui Zhang, Shirley Xin Li, and Yun Kwok Wing. "RBD, Antidepressant Medications, and Psychiatric Disorders." In Rapid-Eye-Movement Sleep Behavior Disorder, 123–34. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-90152-7_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Deacon, Brett J., and Glen I. Spielmans. "Is the Efficacy of “Antidepressant” Medications Overrated?" In Psychological Science Under Scrutiny, 250–70. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2017. http://dx.doi.org/10.1002/9781119095910.ch13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Levine, Stephen B. "The Sexual Side Effects of Serotonergic Antidepressant Medications." In Sexuality in Mid-Life, 151–71. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4899-1942-7_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Serafini, Gianluca, Paola Solano, and Mario Amore. "Antidepressant Medications and Suicide Risk: What Was the Impact of FDA Warning?" In Melatonin, Neuroprotective Agents and Antidepressant Therapy, 477–99. New Delhi: Springer India, 2016. http://dx.doi.org/10.1007/978-81-322-2803-5_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antidepressant medications"

1

Delgado Rodriguez, J., L. Perez Cordon, M. Bitlloch Obiols, S. Marin Rubio, L. Campins Bernadas, V. Aguilera Jimenez, T. Gurrera Roig, and M. Serra Prat. "5PSQ-072 Adequacy of antidepressant medication in elderly patients." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.389.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hooper, Robert, and Tess Compton-Price. "CPAP Therapy improves Depressive Symptoms in OSA Patients, including those using Antidepressant Medication." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Krieg, Anne K., Stefan Hess, and Günter Gauglitz. "Optical sensors for therapeutic drug monitoring of antidepressants for a better medication adjustment." In SPIE Optics + Optoelectronics, edited by Francesco Baldini, Jiri Homola, and Robert A. Lieberman. SPIE, 2013. http://dx.doi.org/10.1117/12.2017417.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jayasooriya, N., SK Saxena, J. Blackwell, I. Petersen, A. Bottle, MH Hotopf, and RC Pollok. "P114 Changing patterns of antidepressant medication use amongst inflammatory bowel disease patients: a UK population-based study." In Abstracts of the BSG Campus, 21–29 January 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2020-bsgcampus.189.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antidepressant medications"

1

Schnabel, Filipina, and Danielle Aldridge. Effectiveness of EHR-Depression Screening Among Adult Diabetics in an Urban Primary Care Clinic. University of Tennessee Health Science Center, April 2021. http://dx.doi.org/10.21007/con.dnp.2021.0003.

Full text
Abstract:
Background Diabetes mellitus (DM) and depression are important comorbid conditions that can lead to more serious health outcomes. The American Diabetes Association (ADA) supports routine screening for depression as part of standard diabetes management. The PHQ2 and PHQ9 questionnaires are good diagnostic screening tools used for major depressive disorders in Type 2 diabetes mellitus (DM2). This quality improvement study aims to compare the rate of depression screening, treatment, and referral to behavioral health in adult patients with DM2 pre and post-integration of depression screening tools into the electronic health record (EHR). Methods We conducted a retrospective chart review on patients aged 18 years and above with a diagnosis of DM2 and no initial diagnosis of depression or other mental illnesses. Chart reviews included those from 2018 or prior for before integration data and 2020 to present for after integration. Sixty subjects were randomly selected from a pool of 33,695 patients in the clinic with DM2 from the year 2013-2021. Thirty of the patients were prior to the integration of depression screening tools PHQ2 and PHQ9 into the EHR, while the other half were post-integration. The study population ranged from 18-83 years old. Results All subjects (100%) were screened using PHQ2 before integration and after integration. Twenty percent of patients screened had a positive PHQ2 among subjects before integration, while 10% had a positive PHQ2 after integration. Twenty percent of patients were screened with a PHQ9 pre-integration which accounted for 100% of those subjects with a positive PHQ2. However, of the 10% of patients with a positive PHQ2 post-integration, only 6.7 % of subjects were screened, which means not all patients with a positive PHQ2 were adequately screened post-integration. Interestingly, 10% of patients were treated with antidepressants before integration, while none were treated with medications in the post-integration group. There were no referrals made to the behavior team in either group. Conclusion There is no difference between the prevalence of depression screening before or after integration of depression screening tools in the EHR. The study noted that there is a decrease in the treatment using antidepressants after integration. However, other undetermined conditions could have influenced this. Furthermore, not all patients with positive PHQ2 in the after-integration group were screened with PHQ9. The authors are unsure if the integration of the depression screens influenced this change. In both groups, there is no difference between referrals to the behavior team. Implications to Nursing Practice This quality improvement study shows that providers are good at screening their DM2 patients for depression whether the screening tools were incorporated in the EHR or not. However, future studies regarding providers, support staff, and patient convenience relating to accessibility and availability of the tool should be made. Additional issues to consider are documentation reliability, hours of work to scan documents in the chart, risk of documentation getting lost, and the use of paper that requires shredding to comply with privacy.
APA, Harvard, Vancouver, ISO, and other styles
2

Some antidepressants can help people quit smoking, but other medications may offer greater benefits. National Institute for Health Research, July 2020. http://dx.doi.org/10.3310/alert_40474.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antidepressant medications' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography